RAF aircraft circling over Swindon ahead of Royal International Air Tattoo
An RAF aircraft has been spotted circling Swindon ahead of the Royal International Air Tattoo.
The Airbus A400M Atlas flew from nearby RAF Brize Norton across the region on Wednesday morning, circling Swindon and Wiltshire.
Sightings of the spectacular jet in Swindon skies may not be uncommon, but residents are always in awe when they see one.
One member of the Swindon and Wiltshire Camera Club snapped the A400M flying past Tadpole Garden Village on Thursday, April 10.
They said they saw the jet "flying pretty low" over Tadpole Garden Village, with another saying they have been plane-spotting from North Meadow.
Flash sale alert🌟 Dive deeper into the stories that shape Swindon with Swindon Advertiser Unlimited local news, an ad-free app, and a digital replica of our print edition—all with 80% fewer ads on our site Subscribe now for a faster news experience - https://t.co/ayrpkI4RBy pic.twitter.com/mkI3QtzrfJ
— Swindon Advertiser (@swindonadver) April 11, 2025
Cold calling 'rogue traders' posing as roofers sparks urgent warning
Music-lovers rejoice as festival returns with 'battle of the bands'
Large market to open at Old Town in Swindon
The Royal Air Force (RAF) operates Airbus A400M, also known as the Atlas C.1, as part of its strategic and tactical airlift capabilities and entered operational service with the RAF in 2014.
The craft can carry a 37-tonne payload over 2,000 nautical miles, capable of operating at altitudes of up to 40,000ft and accommodating up to 116 fully-equipped troops.
On November 17, 2024, the RAF celebrated the 10-year anniversary of the A400M, after the fleet of 22 aircraft was delivered to RAF Brize Norton in 2024.
More than 80,000 people have already secured their spots to see a variety of aircraft at the Royal International Air Tattoo, which is set to take place on Friday, July 18, Saturday, July 19, and Sunday, July 20.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FinReg and CPA.com's alliance targets US
FinReg Global Solutions and have partnered to launch QMCore platform in the US, targeting a market of 18,000 audit and accounting companies. FinReg is an Irish innovator in RegTech, while is the business and technology arm of the American Institute of Certified Public Accountants (AICPA). QMCore is a quality management platform specifically designed for audit firms. This collaboration signifies a notable achievement for FinReg, providing access to a vast market comprising more than 46,000 accounting and audit firms across the US. FinReg is the first Irish enterprise to attain Preferred Partner status with QMCore aims to support audit firms in adapting to changing regulatory requirements, including SQMS No. 1 and QC 1000. Created in Dublin, this adaptable, cloud-based solution streamlines compliance processes and boosts operational efficiency for its clients. The platform delivers a unified system for conducting risk assessments, delegating responsibilities, and maintaining thorough audit trails. This capability is intended to alleviate the administrative challenges that audit firms encounter in their compliance activities. Through Preferred Partner Programme, QMCore will be accessible to a network of 18,000 firms. Established in 2017, FinReg is located in Sandyford Industrial Estate, Dublin, and caters to various sectors, including professional services and healthcare. FinReg Global CEO David Butler said: 'We are delighted with this long-term strategic partnership and it is a great outcome for us to have QMCore recognised as the preferred provider of a quality solution for an organisation such as 'The partnership reflects our commitment to delivering compliance-driven innovation that empowers firms to meet the demands of modern regulation.' "FinReg and alliance targets US" was originally created and published by The Accountant, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
ENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome Patients
LYON, France--(BUSINESS WIRE)--ENYO Pharma ('ENYO'), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases, today announced the smooth continuation of its Phase 2 ALPESTRIA-1 trial in 26 Alport syndrome patients. The topline results from the trial are on track for the fourth quarter of 2025. In parallel, ENYO has finalized its Series C financing round with a €6 million investment from Vesalius Biocapital IV, bringing the total Series C raise to €32 million. The ongoing ALPESTRIA-1 study evaluates Vonafexor, a highly selective and oral FXR agonist, in patients with Alport syndrome, a rare genetic kidney disease with no approved therapy. The trial involves a 24-week ascending doses regimen followed by a 12-week off-treatment observation period. ALPESTRIA-1 was launched mid 2024 in 4 countries (US, F, SP and D) following Orphan Drug Designation from both the FDA and EMA. The new funding from Vesalius Biocapital IV extends ENYO's cash runway through the second half of 2026 and enables the initiation of two new clinical programs: A proof-of-concept trial in patients with Chronic Kidney Disease (CKD) grade 3 and concurrent F2/F3 MASH, building on the promising renal results from the previous Phase 2 LIVIFY clinical study; A PK/PD head-to-head comparison of Vonafexor and its analog EYP651 in healthy subjects. In addition, ENYO will continue to expand its preclinical portfolio, notably in Autosomal Dominant Polycystic Kidney Disease (ADPKD), where the Vonafexor franchise could offer a novel and disease-modifying approach. ' We are pleased with the continued progress of ALPESTRIA-1 and honored to welcome Vesalius Biocapital to our investor syndicate and Dr. Jean-Christophe Renondin as new Board member,' said Dr. Jacky Vonderscher, CEO of ENYO. ' This additional investment will allow us to accelerate the development of our FXR agonist pipeline in both rare and more prevalent kidney diseases. We share a common belief with Vesalius in the transformative potential of Vonafexor and EYP651 for patients suffering from inflammation- and fibrosis-driven renal conditions.' ' Vesalius Biocapital is excited to support ENYO as it progresses into the next phase of clinical development for Vonafexor and its analog EYP651, ' commented Dr. Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV. ' There is an immense need for new treatments in kidney conditions such as Alport Syndrome and CKD. We believe Vonafexor has the potential to help these patients and make a meaningful impact on their lives. I look forward to working with ENYO's excellent leadership team to advance this promising therapeutic candidate.' About ENYO Pharma: ENYO is a clinical-stage biopharmaceutical company headquartered in Lyon (France) and developing proprietary drug candidates to improve quality of life and avoid end stage renal disease and dialysis/transplantation for patients with rare and common kidney diseases. Since its inception ENYO collected extensive phase I/II clinical data through nine completed clinical studies with ca. 400 subjects. ENYO is supported by a strong syndicate of global investors: OrbiMed, Morningside, AndEra, BPIFrance (InnoBio and Large Venture), Sofinnova Partners and Vesalius). For more information: ENYO Pharma About Vesalius Biocapital: Vesalius is a specialist life sciences venture capital investor, investing in companies in later stage companies in drug development, medical device diagnostic and e-health since 2007. Vesalius Biocapital IV, launched in June 2023, targets first and best-in-class European life science companies in drug development and digital health. Its investment portfolio is well balanced between drug development and non-drug development investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs. The team is based in Europe to explore investment opportunities and valuation potential for the portfolio. Managing Partners include Guy Geldhof, Dr Jean-Christophe Renondin and Stéphane Verdood.
Yahoo
12 hours ago
- Yahoo
Council approves hime in pauper attorney funding
The Daviess County Council approved a hefty increase in funding for pauper attorneys in the Daviess Circuit Court. Just six months into the year Daviess Circuit Court Judge Greg Smith went before the council looking for an increase of $150,000 to cover pauper attorney fees for defendants in his court. Council President Marilyn McCullough says there are several reasons for the increase. 'They have had more cases than expected this year,' she said. 'They have been through about 240 cases so far this year and they still have a large number to go through.' Among the issues in circuit court is the change of judge in Daviess Superior Court to former prosecutor Dan Murrie. That has resulted in a slate of cases being kicked to other judges and courts. 'Part of that is that we had a backlog of cases and we are getting caught up on those. Some of those had to be transferred over to Judge Smith because Judge Murrie had been the prosecutor when the cases were filed,' said McCullough. 'Some of those he cannot preside over. We might wind up saving money out of superior court pauper fees.' Courts around the country and in Daviess County fell behind on many of their cases during the COVID outbreak. While there has been a concerted effort to catch those up, that time is still impacting the courts. 'The judges and prosecutor have done a great job,' said McCullough. 'They are trying to streamline processes and try new things to try and clear the backlog created by COVID.' McCullough says she feels the county is approaching the end of the backed up cases. 'We expect this additional appropriation to cover the rest of this year,' she said. 'The courts are clearing out these cases and the end appears to be in sight.' In other business, the council approved a change in the language for the Daviess County Visitor's Bureau form to include questions on number of rooms available and the average daily rate on those rooms. The council tabled taking any action on the CF-1 reports from businesses that are currently holding tax abatements from the county. Council members were wanting more information to see if the companies are complying with the promises they made to receive those tax breaks. The council received an update on a plan to use a kiosk to help probationers during the regular check-ins. They also denied a request for $2,800 in additional funding for inmate needs at the county jail. Daviess County Sheriff Gary Allison said he was hesitant to spend money out of the commissary fund, but will do it that way. The council also accepted a $28,000 grant from the state of Indiana. Central Dispatch Director Julie Riker said the grant would cover 100% of the cost to upgrade the emergency services mapping system. 'It's not going to cost us any money, so that is great,' said McCullough. 'We do need the update.'
